Chris Davis's DGX Position Overview
Chris Davis (via Davis Selected Advisers) currently holds 1.62 M shares of Quest Diagnostics Incorporated (DGX) worth $317.06 M, representing 1.46% of the portfolio. First purchased in 2014-Q1, this long-term strategic position has been held for 49 quarters.
Based on 13F filings since 2013, Chris Davis has maintained a long-term strategic position in DGX, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2014, adding 4.57 M shares. Largest reduction occurred in Q3 2016, reducing 3.04 M shares.
Analysis based on 13F filings available since 2013 Q2
Chris Davis's Quest Diagnostics Incorporated (DGX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Quest Diagnostics Incorporated (DGX) Trades by Chris Davis
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +27,930 | Add 1.76% | 1.62 M | $195.98 |
| Q4 2025 | +228,271 | Add 16.76% | 1.59 M | $173.53 |
| Q3 2025 | +7,192 | Add 0.53% | 1.36 M | $190.58 |
| Q2 2025 | -1.03 M | Reduce 43.29% | 1.35 M | $179.63 |
| Q1 2025 | -8,958 | Reduce 0.37% | 2.39 M | $169.20 |
| Q4 2024 | -1,843 | Reduce 0.08% | 2.4 M | $150.86 |
| Q3 2024 | +8,275 | Add 0.35% | 2.4 M | $155.25 |
| Q2 2024 | +9,665 | Add 0.41% | 2.39 M | $136.88 |
| Q1 2024 | -285,401 | Reduce 10.70% | 2.38 M | $133.11 |
| Q4 2023 | +998,866 | Add 59.89% | 2.67 M | $137.88 |
| Q3 2023 | +153,810 | Add 10.16% | 1.67 M | $121.86 |
| Q2 2023 | -4,864 | Reduce 0.32% | 1.51 M | $140.56 |
| Q1 2023 | -317,071 | Reduce 17.27% | 1.52 M | $141.48 |
| Q4 2022 | -35,337 | Reduce 1.89% | 1.84 M | $156.44 |
| Q3 2022 | -18,655 | Reduce 0.99% | 1.87 M | $122.69 |
| Q2 2022 | -57,243 | Reduce 2.94% | 1.89 M | $132.98 |
| Q1 2022 | -59,570 | Reduce 2.97% | 1.95 M | $136.86 |
| Q4 2021 | -736,328 | Reduce 26.84% | 2.01 M | $173.01 |
| Q3 2021 | -72,658 | Reduce 2.58% | 2.74 M | $145.31 |
| Q2 2021 | +37,508 | Add 1.35% | 2.82 M | $131.97 |
| Q1 2021 | -149,852 | Reduce 5.12% | 2.78 M | $128.34 |
| Q4 2020 | -818,355 | Reduce 21.84% | 2.93 M | $119.17 |
| Q3 2020 | -128,261 | Reduce 3.31% | 3.75 M | $114.49 |
| Q2 2020 | +7,716 | Add 0.20% | 3.87 M | $113.96 |
| Q1 2020 | -37,629 | Reduce 0.96% | 3.87 M | $80.30 |
| Q4 2019 | -73,965 | Reduce 1.86% | 3.9 M | $106.79 |
| Q3 2019 | -22,718 | Reduce 0.57% | 3.98 M | $107.03 |
| Q2 2019 | +362,109 | Add 9.95% | 4 M | $101.81 |
| Q1 2019 | +2.84 M | Add 355.80% | 3.64 M | $89.92 |
| Q4 2018 | +665,853 | Add 502.38% | 798,392 | $83.03 |
| Q3 2018 | -618 | Reduce 0.46% | 132,539 | $107.91 |
| Q2 2018 | -218 | Reduce 0.16% | 133,157 | $109.94 |
| Q1 2018 | +678 | Add 0.51% | 133,375 | $100.30 |
| Q4 2017 | +42 | Add 0.03% | 132,697 | $98.49 |
| Q3 2017 | +66 | Add 0.05% | 132,655 | $93.34 |
| Q2 2017 | +3,170 | Add 2.45% | 132,589 | $111.16 |
| Q1 2017 | -74,279 | Reduce 36.47% | 129,419 | $98.19 |
| Q4 2016 | -36,198 | Reduce 15.09% | 203,698 | $91.90 |
| Q3 2016 | -3.04 M | Reduce 92.68% | 239,896 | $84.63 |
| Q2 2016 | -35,278 | Reduce 1.06% | 3.28 M | $81.41 |
| Q1 2016 | -276,085 | Reduce 7.69% | 3.31 M | $71.45 |
| Q4 2015 | -612,934 | Reduce 14.58% | 3.59 M | $71.14 |
| Q3 2015 | -776,691 | Reduce 15.59% | 4.2 M | $61.47 |
| Q2 2015 | -88,443 | Reduce 1.74% | 4.98 M | $72.52 |
| Q1 2015 | -86,758 | Reduce 1.68% | 5.07 M | $76.85 |
| Q4 2014 | +276,267 | Add 5.66% | 5.16 M | $67.06 |
| Q3 2014 | +206,735 | Add 4.42% | 4.88 M | $60.68 |
| Q2 2014 | +4.57 M | Add 4465.97% | 4.67 M | $58.69 |
| Q1 2014 | +102,337 | New Buy | 102,337 | $57.92 |
Chris Davis's Quest Diagnostics Incorporated Investment FAQs
Chris Davis first purchased Quest Diagnostics Incorporated (DGX) in Q1 2014, acquiring 102,337 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chris Davis has held Quest Diagnostics Incorporated (DGX) for 49 quarters since Q1 2014.
Chris Davis's largest addition to Quest Diagnostics Incorporated (DGX) was in Q2 2014, adding 4,672,681 shares worth $274.24 M.
According to the latest 13F filing for Q1 2026, Chris Davis's firm, Davis Selected Advisers, owns 1,617,813 shares of Quest Diagnostics Incorporated (DGX), valued at approximately $317.06 M.
As of the Q1 2026 filing, Quest Diagnostics Incorporated (DGX) represents approximately 1.46% of Chris Davis's publicly disclosed stock portfolio, making it one of their key holdings.
Chris Davis's peak holding in Quest Diagnostics Incorporated (DGX) was 5,155,683 shares, as reported at the end of Q4 2014.